Compare MNSO & IMVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MNSO | IMVT |
|---|---|---|
| Founded | 2013 | 2018 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Department/Specialty Retail Stores | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.8B | 5.3B |
| IPO Year | 2020 | N/A |
| Metric | MNSO | IMVT |
|---|---|---|
| Price | $19.84 | $27.55 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 10 |
| Target Price | $24.10 | ★ $27.75 |
| AVG Volume (30 Days) | 678.0K | ★ 2.0M |
| Earning Date | 11-20-2025 | 02-05-2026 |
| Dividend Yield | ★ 3.33% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.98 | N/A |
| Revenue | ★ $2,795,603,723.00 | N/A |
| Revenue This Year | $27.64 | N/A |
| Revenue Next Year | $19.31 | N/A |
| P/E Ratio | $20.04 | ★ N/A |
| Revenue Growth | ★ 23.44 | N/A |
| 52 Week Low | $13.95 | $12.72 |
| 52 Week High | $27.71 | $27.69 |
| Indicator | MNSO | IMVT |
|---|---|---|
| Relative Strength Index (RSI) | 46.22 | 69.17 |
| Support Level | $19.35 | $25.84 |
| Resistance Level | $20.34 | $27.69 |
| Average True Range (ATR) | 0.35 | 1.38 |
| MACD | 0.10 | 0.28 |
| Stochastic Oscillator | 62.92 | 97.50 |
MINISO Group Holding Ltd is a value retailer offering a variety of trendy lifestyle products featuring IP design. The principal activity of the Company is investment holding. The company's product categories include home decor, small electronics, textiles, accessories, beauty tools, toys, cosmetics, personal care, snacks, fragrance and perfumes, and stationery and gifts. Its segment includes the MINISO brand, which is engaged in the Design, buying, and sale of lifestyle products, and the TOP TOY brand, which is engaged in the Design, buying, and sale of pop toys. The company generates maximum revenue from the MINISO brand segment. Geographically, it derives a majority of its revenue from China.
Immunovant Inc is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. Its focus is on developing IMVT-1402, a potential inhibitor of the neonatal fragment crystallizable receptor (FcRn), to address autoimmune diseases driven by high levels of pathogenic immunoglobulin G (IgG) antibodies. FcRn is involved in preventing the degradation of IgG antibodies, and inhibition of FcRn has been shown to reduce levels of total IgG and pathogenic IgG antibodies. The company operates in a single operating segment, which includes all activities related to the research, development and manufacturing of its product candidates.